Eisai and Pfizer
LONDON, July 18, 2011 -
Higher Levels of
Social Assistance and Less Autonomy in This Group of
Patients
Results from a new French study reveal that nearly half of newly
diagnosed patients with mild Alzheimer's disease also suffer from
apathy and depression.
LONDON, March 23, 2011 - Alzheimer's patients in England and Wales can now be prescribed treatment
when presenting with mild stages of the disease.
LONDON, October 7, 2010 - The National Institute for Health and Clinical Excellence (NICE) has
today announced new draft guidance which represents a significant step
towards ensuring patients with Alzheimer's disease in England and Wales
receive treatment for their condition, from the early stages of disease.
LONDON -
- NICE Commit to Reviewing Existing Guidance 'As Soon As Possible'
On June 11, the National Institute for Health and Clinical Excellence (NICE) announced that, following consultation with stakeholders on the economic model that underpinned NICE's 2006 guidance on the use of drugs to treat Alzheimer's disease, the guidance remains unchanged despite recognising significant errors within their model.
LONDON - Mild Alzheimer's Patients Continue to be Denied Treatment
Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, have been notified by the National Institute for Health and Clinical Excellence (NICE) of their decision to continue to deny vulnerable patients the use of anti-cholinergic medicines in the treatment of mild Alzheimer's disease.
